Testosterone Therapy in Glucocorticoid-Treated Men

Reid, Ian R.

doi:10.1001/archinte.1996.00440100065008

Cited by 318 publications

(74 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…34 Glucocorticoids also reduce osteoclast apoptosis, 35 thus increasing bone resorption and increase osteocyte apoptosis, an effect that is implicated in the development of avascular necrosis. 35 Indirect effects of glucocorticoids also con- tribute to bone loss; these include hypogonadism, 36 reduced intestinal calcium absorption 37 and increased renal calcium excretion. 38 Glucocorticoid-induced bone loss is particularly rapid in the first few months of therapy and affects both cortical and cancellous bone.…”

Section: Glucocorticoidsmentioning

confidence: 99%

Osteoporosis after liver transplantation

Compston

2003

Liver Transplantation

107

View full text Add to dashboard Cite

L iver transplantation is now a well-established procedure with 5-year survival rates of over 70% in most centers. 1 The quality of life for the majority of survivors is good, but a number of long-term complications have been described, many of which are related to immunosuppressive therapy. The main skeletal complications are avascular necrosis and osteoporosis, of which the latter is most common and may result in significant morbidity and mortality.Studies performed early in the history of liver transplantation documented rapid bone loss and a high incidence of fragility fractures, but there is evidence that the frequency of osteoporosis after transplantation may be decreasing, providing important insights into its pathogenesis. This review considers the clinical features, pathogenesis, pathophysiology, and management of osteoporosis after liver transplantation and considers the lessons that may be learnt from changes in its natural history. Clinical FeaturesOsteoporosis is characterised by reduced bone mass and disruption of bone architecture, leading to decreased bone strength and an increase in the risk of fragility fracture particularly at the wrist, hip and spine. 2 These fractures are associated with a high morbidity and increased mortality and often have devastating effects on quality of life.

show abstract

Section: Glucocorticoidsmentioning

confidence: 99%

Osteoporosis after liver transplantation

Compston

2003

Liver Transplantation

107

View full text Add to dashboard Cite

show abstract

“…In asthmatic men receiving long-term GC treatment, testosterone treatment was shown to increase lumbar spine BMD by 5.0% over 12 months [108]. In women treated with GCs for rheumatic disease, nandrolone decanoate significantly increased forearm bone density by 5.1% over 18 months versus baseline (P<0.01) [3].…”

Section: Fluoridementioning

confidence: 92%

Glucocorticosteroid-induced spinal osteoporosis: scientific update on pathophysiology and treatment

et al. 2006

View full text Add to dashboard Cite

“…Serum testosterone concentrations correlate positively with muscle mass and negatively with fat mass [57]. Testosterone replacement therapy increases lean body mass in men with hypogonadism due to aging, HIV infection, and other chronic diseases [58][59][60]. Some but not all studies have reported that testosterone replacement therapy decreases fat mass in hypogonadal men [58,61,62].…”

Section: Treatment-related Changes In Body Compositionmentioning

confidence: 99%

Androgen deprivation therapy for prostate cancer: new concepts and concerns

Smith

2007

Current Opinion in Endocrinology, Diabetes &Amp; Obesity

148

129

View full text Add to dashboard Cite

Purpose of review-The aim of this review is to summarize new concepts and concerns regarding treatment-related osteoporosis, diabetes, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.Recent findings-Gonadotropin-releasing hormone agonists increase bone turnover, decrease bone mineral density, and increase fracture risk. Bisphosphonates, selective and estrogen receptor modulators significantly increase bone mineral density during androgen deprivation therapy. Ongoing randomized controlled trials will assess efficacy of denosumab, toremifene, and zoledronic acid to prevent fractures in this setting. Gonadotropin-releasing hormone agonists also increase fat mass, decrease insulin sensitivity, and increase serum lipoproteins. In contrast to the classical metabolic syndrome, however, the phenotype of men during androgen deprivation therapy is characterized by increased high-density lipoprotein cholesterol and preferential accumulation of subcutaneous fat. Gonadotropin-releasing hormone agonists are associated with greater risk of incident diabetes and cardiovascular disease in men with prostate cancer.Summary-Androgen therapy increases risk of fractures, diabetes mellitus, and cardiovascular disease in men with prostate cancer. Current and planned studies will evaluate strategies to prevent these treatment-related adverse effects.

show abstract

Testosterone Therapy in Glucocorticoid-Treated Men

Abstract: Testosterone treatment reverses the deleterious effects glucocorticoid drugs on skeletal and soft tissues in men.

Cited by 318 publications

References 27 publications

Osteoporosis after liver transplantation

Osteoporosis after liver transplantation

Glucocorticosteroid-induced spinal osteoporosis: scientific update on pathophysiology and treatment

Androgen deprivation therapy for prostate cancer: new concepts and concerns

Contact Info

Product

Resources

About